Biotech: No Downside Risk Here – Barron’s

Posted: Published on June 1st, 2017

This post was added by Dr P. Richardson


BNB Daily (blog)
Biotech: No Downside Risk Here
Barron's
Both the iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 1.5% and 2.4% respectively, so far on Thursday. Oppenheimer's Leah Rush Cann notes that biotech stocks are trading at a 30% premium to the market.
iShares NASDAQ Biotechnology Index (IBB) Stake Reduced by NF Trinity Capital Hong Kong LtdThe Cerbat Gem
iShares NASDAQ Biotechnology Index (IBB) Position Raised by Blair William & Co. ILBNB Daily (blog)
Alethea Capital Management LLC Maintains Stake in iShares NASDAQ Biotechnology Index (IBB)Chaffey Breeze
BBNS -Sports Perspectives -Markets Daily
all 16 news articles »

Read the original:
Biotech: No Downside Risk Here - Barron's

Related Posts
This entry was posted in Biotechnology. Bookmark the permalink.

Comments are closed.